154 related articles for article (PubMed ID: 34628621)
21. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women.
Bhatla N; Suri V; Basu P; Shastri S; Datta SK; Bi D; Descamps DJ; Bock HL;
J Obstet Gynaecol Res; 2010 Feb; 36(1):123-32. PubMed ID: 20178538
[TBL] [Abstract][Full Text] [Related]
22. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.
Naud PS; Roteli-Martins CM; De Carvalho NS; Teixeira JC; de Borba PC; Sanchez N; Zahaf T; Catteau G; Geeraerts B; Descamps D
Hum Vaccin Immunother; 2014; 10(8):2147-62. PubMed ID: 25424918
[TBL] [Abstract][Full Text] [Related]
23. Roles of vaginal flora in human papillomavirus infection, virus persistence and clearance.
Zeng M; Li X; Jiao X; Cai X; Yao F; Xu S; Huang X; Zhang Q; Chen J
Front Cell Infect Microbiol; 2022; 12():1036869. PubMed ID: 36683675
[TBL] [Abstract][Full Text] [Related]
24. Changes in vaginal microbiome after focused ultrasound treatment of high-risk human papillomavirus infection-related low-grade cervical lesions.
Wang W; Liu Y; Yang Y; Ren J; Zhou H
BMC Infect Dis; 2023 Jan; 23(1):3. PubMed ID: 36604622
[TBL] [Abstract][Full Text] [Related]
25. A novel sequencing-based vaginal health assay combining self-sampling, HPV detection and genotyping, STI detection, and vaginal microbiome analysis.
Bik EM; Bird SW; Bustamante JP; Leon LE; Nieto PA; Addae K; Alegría-Mera V; Bravo C; Bravo D; Cardenas JP; Carson GA; Caughey A; Covarrubias PC; Pérez-Donoso J; Gass G; Gupta SL; Harman K; Hongo DMB; Jiménez JC; Kraal L; Melis-Arcos F; Morales EH; Morton A; Navas CF; Nuñez H; Olivares E; Órdenes-Aenishanslins N; Ossandon FJ; Phan R; Pino R; Soto-Liebe K; Varas I; Vera-Wolf P; Walton NA; Almonacid DE; Goddard AD; Ugalde JA; Zneimer S; Richman J; Apte ZS
PLoS One; 2019; 14(5):e0215945. PubMed ID: 31042762
[TBL] [Abstract][Full Text] [Related]
26. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix.
Schwarz TF
Adv Ther; 2009 Nov; 26(11):983-98. PubMed ID: 20024678
[TBL] [Abstract][Full Text] [Related]
27. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
Schwarz TF
Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
[TBL] [Abstract][Full Text] [Related]
28. The Vaginal Microbiome of Nonhuman Primates Can Be Only Transiently Altered to Become
Langner CA; Ortiz AM; Flynn JK; Kendall H; Lagenaur LA; Brenchley JM
Microbiol Spectr; 2021 Dec; 9(3):e0107421. PubMed ID: 34756073
[TBL] [Abstract][Full Text] [Related]
29. The vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women: a cross-sectional analysis.
Borgogna JC; Shardell MD; Santori EK; Nelson TM; Rath JM; Glover ED; Ravel J; Gravitt PE; Yeoman CJ; Brotman RM
BJOG; 2020 Jan; 127(2):182-192. PubMed ID: 31749298
[TBL] [Abstract][Full Text] [Related]
30. Associations between the vaginal microbiome and Candida colonization in women of reproductive age.
Tortelli BA; Lewis WG; Allsworth JE; Member-Meneh N; Foster LR; Reno HE; Peipert JF; Fay JC; Lewis AL
Am J Obstet Gynecol; 2020 May; 222(5):471.e1-471.e9. PubMed ID: 31654610
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years.
Petäjä T; Keränen H; Karppa T; Kawa A; Lantela S; Siitari-Mattila M; Levänen H; Tocklin T; Godeaux O; Lehtinen M; Dubin G
J Adolesc Health; 2009 Jan; 44(1):33-40. PubMed ID: 19101456
[TBL] [Abstract][Full Text] [Related]
32. Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women.
Dareng EO; Ma B; Famooto AO; Adebamowo SN; Offiong RA; Olaniyan O; Dakum PS; Wheeler CM; Fadrosh D; Yang H; Gajer P; Brotman RM; Ravel J; Adebamowo CA
Epidemiol Infect; 2016 Jan; 144(1):123-37. PubMed ID: 26062721
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix].
Keam SJ; Harper DM
Drugs; 2008; 68(3):359-72. PubMed ID: 18257611
[TBL] [Abstract][Full Text] [Related]
34. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
Zhu FC; Hu SY; Hong Y; Hu YM; Zhang X; Zhang YJ; Pan QJ; Zhang WH; Zhao FH; Zhang CF; Yang X; Yu JX; Zhu J; Zhu Y; Chen F; Zhang Q; Wang H; Wang C; Bi J; Xue S; Shen L; Zhang YS; He Y; Tang H; Karkada N; Suryakiran P; Bi D; Struyf F
Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial of the immunogenicity and safety of the Hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine.
Leroux-Roels G; Haelterman E; Maes C; Levy J; De Boever F; Licini L; David MP; Dobbelaere K; Descamps D
Clin Vaccine Immunol; 2011 Sep; 18(9):1510-8. PubMed ID: 21734063
[TBL] [Abstract][Full Text] [Related]
36. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
[TBL] [Abstract][Full Text] [Related]
37. The Cervicovaginal Microbiota and Its Associations With Human Papillomavirus Detection in HIV-Infected and HIV-Uninfected Women.
Reimers LL; Mehta SD; Massad LS; Burk RD; Xie X; Ravel J; Cohen MH; Palefsky JM; Weber KM; Xue X; Anastos K; Minkoff H; Atrio J; D'Souza G; Ye Q; Colie C; Zolnik CP; Spear GT; Strickler HD
J Infect Dis; 2016 Nov; 214(9):1361-1369. PubMed ID: 27521363
[TBL] [Abstract][Full Text] [Related]
38. Vaginal Microbiome Components as Correlates of Cervical Human Papillomavirus Infection.
Andrade Pessoa Morales J; Marconi C; El-Zein M; Ravel J; da Silva Pinto GV; Silveira R; Lima MD; de Carvalho NS; Alves RRF; de Lima Parada CMG; Leite SHM; Villa LL; Franco EL; da Silva MG
J Infect Dis; 2022 Sep; 226(6):1084-1097. PubMed ID: 34718662
[TBL] [Abstract][Full Text] [Related]
39. Vaginal microbiota and human papillomavirus infection among young Swedish women.
Cheng L; Norenhag J; Hu YOO; Brusselaers N; Fransson E; Ährlund-Richter A; Guðnadóttir U; Angelidou P; Zha Y; Hamsten M; Schuppe-Koistinen I; Olovsson M; Engstrand L; Du J
NPJ Biofilms Microbiomes; 2020 Oct; 6(1):39. PubMed ID: 33046723
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.
Medina DM; Valencia A; de Velasquez A; Huang LM; Prymula R; García-Sicilia J; Rombo L; David MP; Descamps D; Hardt K; Dubin G;
J Adolesc Health; 2010 May; 46(5):414-21. PubMed ID: 20413076
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
